Longeveron LGVN
NASDAQ LGVN
$0.84 +0.02 (+2.02%)
At close: Aug 21, 2026 · 4:00 PM EDT

Longeveron (LGVN) Share-based Compensation (2020 - 2026)

Longeveron (LGVN) posted quarterly Share-based Compensation of $379000.0 for Q1 2026, up 11.47% year-over-year from $340000.0 in Q1 2025, and up 0.8% quarter-over-quarter from $376000.0 in Q4 2025.

Longeveron (LGVN) Share-based Compensation (2020 - 2026) Analysis & Trends

Longeveron's Share-based Compensation history runs 7 years deep, the most recent figure standing at $379000.0 for Q1 2026.

  • In Q1 2026, Share-based Compensation rose 11.47% year-over-year to $379000.0; the TTM figure through Mar 2026 stood at $1.7 million (down 27.69% YoY), while the FY2025 annual figure was $1.7 million, down 27.96% from the prior year.
  • Share-based Compensation for Q1 2026 stood at $379000.0, up from $376000.0 in the prior quarter.
  • The five-year high for Share-based Compensation was $1.4 million in Q3 2024, with the low at $230000.0 in Q2 2024.
  • The 5-year median for Share-based Compensation is $448000.0 (2025), against an average of $526647.1.
  • Peak annual rise in Share-based Compensation reached 312.61% in 2022, while the deepest fall reached 89.49% in 2022.
  • Longeveron's Share-based Compensation stood at $646000.0 in 2022, then plunged by 36.07% to $413000.0 in 2023, then declined by 5.57% to $390000.0 in 2024, then declined by 3.59% to $376000.0 in 2025, then grew by 0.8% to $379000.0 in 2026.
  • Business Quant data shows LGVN's Share-based Compensation at $379000.0 in Q1 2026, $376000.0 in Q4 2025, and $448000.0 in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Stock Comp. (Qtr)
1 Vertex Pharmaceuticals 139.13 Bn 131.28 Bn 2.84 Bn 108.10 Mn
2 Regeneron Pharmaceuticals 85.77 Bn 77.77 Bn 3.93 Bn 243.00 Mn
3 Argenx Se 64.64 Bn 59.46 Bn 1.37 Bn -
4 Moderna 58.29 Bn 53.16 Bn 52.00 Mn 120.00 Mn
5 BeOne Medicines 41.92 Bn 36.82 Bn 1.53 Bn 137.41 Mn
6 Alnylam Pharmaceuticals 31.58 Bn 28.28 Bn 992.69 Mn 86.63 Mn
7 BioNTech SE 28.12 Bn 9.73 Bn 668.28 Mn 28.05 Mn
8 Insmed 27.39 Bn 26.22 Bn 358.27 Mn 41.25 Mn
9 Royalty Pharma 27.27 Bn 26.43 Bn - -
10 Longeveron 26.51 Mn 16.41 Mn 182,000.00 373,000.00

Historic Data

Download Data
DateValue
Jun 30, 2026 373,000.00
Jun 30, 2026 373,000.00
Mar 31, 2026 379,000.00
Mar 31, 2026 379,000.00
Dec 31, 2025 376,000.00
Dec 31, 2025 376,000.00
Sep 30, 2025 448,000.00
Sep 30, 2025 448,000.00
Jun 30, 2025 513,000.00
Jun 30, 2025 513,000.00
Mar 31, 2025 340,000.00
Mar 31, 2025 340,000.00
Dec 31, 2024 390,000.00
Dec 31, 2024 390,000.00
Sep 30, 2024 1.41 Mn
Sep 30, 2024 1.41 Mn
Jun 30, 2024 230,000.00
Jun 30, 2024 230,000.00
Mar 31, 2024 295,000.00
Mar 31, 2024 295,000.00